{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:56:08Z","timestamp":1792605368612,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T00:00:00Z","timestamp":1768608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10557-025-07830-x","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T09:14:24Z","timestamp":1768641264000},"page":"1575-1593","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Modulating CGRP Signaling: A Promising Therapeutic Avenue for Attenuating Cardiac Dysfunction in Heart Failure"],"prefix":"10.1007","volume":"40","author":[{"given":"Shazia","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2450-2975","authenticated-orcid":false,"given":"Khadga Raj","family":"Aran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"issue":"3","key":"7830_CR1","doi-asserted-by":"publisher","first-page":"102968","DOI":"10.1016\/j.cpcardiol.2024.102968","volume":"50","author":"E Johnson","year":"2025","unstructured":"Johnson E, Albakri JS, Allemailem KS, et al. Mitochondrial dysfunction and calcium homeostasis in heart failure: exploring the interplay between oxidative stress and cardiac remodeling for future therapeutic innovations. Curr Probl Cardiol. 2025;50(3):102968. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102968.","journal-title":"Curr Probl Cardiol"},{"issue":"2","key":"7830_CR2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.15420\/cfr.2015.1.2.90","volume":"1","author":"P Pellicori","year":"2015","unstructured":"Pellicori P, Kaur K, Clark AL. Fluid management in patients with chronic heart failure. Card Fail Rev. 2015;1(2):90\u20135. https:\/\/doi.org\/10.15420\/cfr.2015.1.2.90.","journal-title":"Card Fail Rev"},{"key":"7830_CR3","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.15420\/cfr.2023.05","volume":"9","author":"B Shahim","year":"2023","unstructured":"Shahim B, Kapelios CJ, Savarese G, Lund LH. Global public health burden of heart failure: an updated review. Card Fail Rev. 2023;9:e11. https:\/\/doi.org\/10.15420\/cfr.2023.05.","journal-title":"Card Fail Rev"},{"key":"7830_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.21037\/amj.2020.03.03","volume":"5","author":"G Lippi","year":"2020","unstructured":"Lippi G, Sanchis-Gomar F. Global epidemiology and future trends of heart failure. AME Med J. 2020;5:28. https:\/\/doi.org\/10.21037\/amj.2020.03.03.","journal-title":"AME Med J"},{"issue":"4","key":"7830_CR5","doi-asserted-by":"publisher","first-page":"102411","DOI":"10.1016\/j.cpcardiol.2024.102411","volume":"49","author":"TP Varghese","year":"2024","unstructured":"Varghese TP, Tazneem B. Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). Curr Probl Cardiol. 2024;49(4):102411. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102411.","journal-title":"Curr Probl Cardiol"},{"issue":"1","key":"7830_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","volume":"14","author":"J Hartupee","year":"2017","unstructured":"Hartupee J, Mann DL. Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 2017;14(1):30\u20138. https:\/\/doi.org\/10.1038\/nrcardio.2016.163.","journal-title":"Nat Rev Cardiol"},{"issue":"20","key":"7830_CR7","doi-asserted-by":"publisher","first-page":"15472","DOI":"10.3390\/ijms242015472","volume":"24","author":"AA Manolis","year":"2023","unstructured":"Manolis AA, Manolis TA, Manolis AS. Neurohumoral activation in heart failure. Int J Mol Sci. 2023;24(20):15472. https:\/\/doi.org\/10.3390\/ijms242015472.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"7830_CR8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1152\/physrev.00034.2013","volume":"94","author":"FA Russell","year":"2014","unstructured":"Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014;94(4):1099\u2013142. https:\/\/doi.org\/10.1152\/physrev.00034.2013.","journal-title":"Physiol Rev"},{"key":"7830_CR9","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3389\/fphys.2018.01249","volume":"9","author":"Z Kee","year":"2018","unstructured":"Kee Z, Kodji X, Brain SD. The role of calcitonin gene-related peptide (CGRP) in neurogenic vasodilation and its cardioprotective effects. Front Physiol. 2018;9:1249. https:\/\/doi.org\/10.3389\/fphys.2018.01249.","journal-title":"Front Physiol"},{"key":"7830_CR10","doi-asserted-by":"publisher","first-page":"833645","DOI":"10.3389\/fphys.2022.833645","volume":"13","author":"F Argunhan","year":"2022","unstructured":"Argunhan F, Brain SD. The vascular-dependent and -independent actions of calcitonin gene-related peptide in cardiovascular disease. Front Physiol. 2022;13:833645. https:\/\/doi.org\/10.3389\/fphys.2022.833645.","journal-title":"Front Physiol"},{"issue":"1","key":"7830_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","volume":"20","author":"V Favoni","year":"2019","unstructured":"Favoni V, Giani L, Al-Hassany L, et al. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain. 2019;20(1):27. https:\/\/doi.org\/10.1186\/s10194-019-0979-y.","journal-title":"J Headache Pain"},{"key":"7830_CR12","unstructured":"Saboowala H. Calcitonin gene-related peptide (CGRP): insights into its physiological functions and pathological implications. Dr Hakim Saboowala Rep 2024."},{"issue":"2","key":"7830_CR13","doi-asserted-by":"publisher","first-page":"e213852","DOI":"10.1212\/WNL.0000000000213852","volume":"105","author":"MT Eller","year":"2025","unstructured":"Eller MT, Schwarzov\u00e1 K, Gufler L, et al. CGRP-targeted migraine therapies in patients with vascular risk factors or stroke: a review. Neurology. 2025;105(2):e213852. . https:\/\/doi.org\/10.1212\/WNL.0000000000213852","journal-title":"Neurology"},{"issue":"3","key":"7830_CR14","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/bph.15605","volume":"179","author":"TA Rees","year":"2022","unstructured":"Rees TA, Hendrikse ER, Hay DL, Walker CS, Beyond CGRP. The calcitonin peptide family as targets for migraine and pain. Br J Pharmacol. 2022;179(3):381\u201399. https:\/\/doi.org\/10.1111\/bph.15605.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"7830_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1210\/edrv-17-5-533","volume":"17","author":"SJ Wimalawansa","year":"1996","unstructured":"Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev. 1996;17(5):533\u201385. https:\/\/doi.org\/10.1210\/edrv-17-5-533.","journal-title":"Endocr Rev"},{"issue":"2","key":"7830_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0167-4781(80)90013-5","volume":"1008","author":"RA Bovenberg","year":"1989","unstructured":"Bovenberg RA, Moen TC, Jansz HS, Baas PD. In vitro splicing analysis of mini-gene constructs of the alternatively processed human calcitonin\/CGRP-I pre-mRNA. Biochim Biophys Acta Gene Struct Expr. 1989;1008(2):223\u201333. https:\/\/doi.org\/10.1016\/0167-4781(80)90013-5.","journal-title":"Biochim Biophys Acta Gene Struct Expr"},{"issue":"2","key":"7830_CR17","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.tips.2010.06.006","volume":"19","author":"K Makowska","year":"2018","unstructured":"Makowska K, Gonkowski S. The influence of inflammation and nerve damage on the neurochemical characterization of calcitonin gene-related peptide\u2013like immunoreactive (CGRP-LI) neurons in the enteric nervous system of the Porcine descending colon. Int J Mol Sci. 2018;19(2):548. https:\/\/doi.org\/10.1016\/j.tips.2010.06.006.","journal-title":"Int J Mol Sci"},{"key":"7830_CR18","doi-asserted-by":"publisher","first-page":"821","DOI":"10.3389\/fphys.2019.00821","volume":"10","author":"A Kumar","year":"2019","unstructured":"Kumar A, Potts JD, DiPette DJ. Protective role of \u03b1-calcitonin gene-related peptide in cardiovascular diseases. Front Physiol. 2019;10:821. https:\/\/doi.org\/10.3389\/fphys.2019.00821.","journal-title":"Front Physiol"},{"issue":"Suppl 1","key":"7830_CR19","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1111\/j.1526-4610.2006.00483.x","volume":"46","author":"PL Durham","year":"2006","unstructured":"Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache. 2006;46(Suppl 1):S3\u20138. https:\/\/doi.org\/10.1111\/j.1526-4610.2006.00483.x.","journal-title":"Headache"},{"key":"7830_CR20","doi-asserted-by":"publisher","unstructured":"Aksoydan B, Durdagi S. Molecular simulations reveal the impact of RAMP1 on ligand binding and dynamics of CGRPR heterodimer. BioRxiv. 2021 May 10. https:\/\/doi.org\/10.1101\/2021.05.10.443383.","DOI":"10.1101\/2021.05.10.443383"},{"issue":"3","key":"7830_CR21","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/aps.2011.170","volume":"33","author":"K Pal","year":"2012","unstructured":"Pal K, Melcher K, Xu HE. Structure and mechanism for recognition of peptide hormones by class B G-protein-coupled receptors. Acta Pharmacol Sin. 2012;33(3):300\u201311. https:\/\/doi.org\/10.1038\/aps.2011.170.","journal-title":"Acta Pharmacol Sin"},{"issue":"2","key":"7830_CR22","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.apsb.2021.07.028","volume":"12","author":"L Shao","year":"2022","unstructured":"Shao L, Chen Y, Zhang S, et al. Modulating effects of ramps on signaling profiles of the glucagon receptor family. Acta Pharm Sin B. 2022;12(2):637\u201350. https:\/\/doi.org\/10.1016\/j.apsb.2021.07.028.","journal-title":"Acta Pharm Sin B"},{"issue":"12","key":"7830_CR23","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.mad.2008.09.017","volume":"129","author":"SR Farrell","year":"2008","unstructured":"Farrell SR, Howlett SE. The age-related decrease in catecholamine sensitivity is mediated by beta(1)-adrenergic receptors linked to a decrease in adenylate cyclase activity in ventricular myocytes from male Fischer 344 rats. Mech Ageing Dev. 2008;129(12):735\u201344. https:\/\/doi.org\/10.1016\/j.mad.2008.09.017.","journal-title":"Mech Ageing Dev"},{"key":"7830_CR24","doi-asserted-by":"publisher","first-page":"925692","DOI":"10.3389\/fcvm.2022.925692","volume":"9","author":"A Mahmood","year":"2022","unstructured":"Mahmood A, Ahmed K, Zhang Y. \u03b2-adrenergic receptor desensitization\/down-regulation in heart failure: A friend or foe? Front Cardiovasc Med. 2022;9:925692. https:\/\/doi.org\/10.3389\/fcvm.2022.925692.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"7830_CR25","doi-asserted-by":"publisher","first-page":"922","DOI":"10.3390\/cells10040922","volume":"10","author":"AS Colombe","year":"2021","unstructured":"Colombe AS, Pidoux G. Cardiac cAMP-PKA signaling compartmentalization in myocardial infarction. Cells. 2021;10(4):922. https:\/\/doi.org\/10.3390\/cells10040922.","journal-title":"Cells"},{"issue":"6","key":"7830_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1177\/1756285610388343","volume":"3","author":"S Eftekhari","year":"2010","unstructured":"Eftekhari S, Edvinsson L. Possible sites of action of the new calcitonin gene-related peptide receptor antagonists. Ther Adv Neurol Disord. 2010;3(6):369\u201378. https:\/\/doi.org\/10.1177\/1756285610388343.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"7830_CR27","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/1523-1747.ep12455620","volume":"87","author":"SD Brain","year":"1986","unstructured":"Brain SD, Tippins JR, Morris HR, et al. Potent vasodilator activity of calcitonin gene-related peptide in human skin. J Invest Dermatol. 1986;87(4):533\u20136. https:\/\/doi.org\/10.1111\/1523-1747.ep12455620.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"7830_CR28","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1161\/01.RES.86.8.897","volume":"86","author":"RE White","year":"2000","unstructured":"White RE, Kryman JP, El-Mowafy AM, et al. cAMP-dependent vasodilators cross-activate the cGMP-dependent protein kinase to stimulate BK\u2009<\u2009sub\u2009>\u2009Ca\u2009channel activity in coronary artery smooth muscle cells. Circ Res. 2000;86(8):897\u2013905. https:\/\/doi.org\/10.1161\/01.RES.86.8.897.","journal-title":"Circ Res"},{"issue":"3","key":"7830_CR29","doi-asserted-by":"publisher","first-page":"349","DOI":"10.4274\/tjps.galenos.2019.47123","volume":"17","author":"G Tell\u0130","year":"2020","unstructured":"Tell\u0130 G, Tel BC, G\u00dcm\u00dc\u015eel B. The cardiopulmonary effects of the calcitonin gene-related peptide family. Turk J Pharm Sci. 2020;17(3):349. https:\/\/doi.org\/10.4274\/tjps.galenos.2019.47123.","journal-title":"Turk J Pharm Sci"},{"issue":"1","key":"7830_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000028339","volume":"60","author":"A Franco-Cereceda","year":"2000","unstructured":"Franco-Cereceda A, Liska J. Potential of calcitonin gene-related peptide in coronary heart disease. Pharmacology. 2000;60(1):1\u20138. https:\/\/doi.org\/10.1159\/000028339.","journal-title":"Pharmacology"},{"issue":"3","key":"7830_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8","volume":"190","author":"H Li","year":"2000","unstructured":"Li H, F\u00f6rstermann U. Nitric oxide in the pathogenesis of vascular disease. J Pathol. 2000;190(3):244\u201354. https:\/\/doi.org\/10.1002\/(SICI)1096-9896(200002)190:3%3C244::AID-PATH575%3E3.0.CO;2-8.","journal-title":"J Pathol"},{"issue":"6","key":"7830_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/0033-0620(82)90008-2","volume":"24","author":"R Zelis","year":"1982","unstructured":"Zelis R, Flaim SF. Alterations in vasomotor tone in congestive heart failure. Prog Cardiovasc Dis. 1982;24(6):437\u201359. https:\/\/doi.org\/10.1016\/0033-0620(82)90008-2.","journal-title":"Prog Cardiovasc Dis"},{"issue":"1","key":"7830_CR33","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/0002-9343(78)90700-3","volume":"65","author":"DT Mason","year":"1978","unstructured":"Mason DT. Afterload reduction and cardiac performance: physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure. Am J Med. 1978;65(1):106\u201325. https:\/\/doi.org\/10.1016\/0002-9343(78)90700-3.","journal-title":"Am J Med"},{"issue":"5","key":"7830_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/0022-4804(90)90192-5","volume":"49","author":"CD Joyce","year":"1990","unstructured":"Joyce CD, Prinz RA, Thomas JX, et al. Calcitonin gene-related peptide increases coronary flow and decreases coronary resistance. J Surg Res. 1990;49(5):435\u201340. https:\/\/doi.org\/10.1016\/0022-4804(90)90192-5.","journal-title":"J Surg Res"},{"issue":"4","key":"7830_CR35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1161\/CIRCULATIONAHA.117.028388","volume":"136","author":"AA Aubdool","year":"2017","unstructured":"Aubdool AA, Thakore P, Argunhan F, et al. A novel \u03b1-calcitonin gene-related peptide analogue protects against end-organ damage in experimental hypertension, cardiac hypertrophy, and heart failure. Circulation. 2017;136(4):367\u201383. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.028388.","journal-title":"Circulation"},{"issue":"4","key":"7830_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/CH-201032","volume":"77","author":"BH Li","year":"2021","unstructured":"Li BH, Fang KF, Lin PH, et al. Effect of sacubitril Valsartan on cardiac function and endothelial function in patients with chronic heart failure with reduced ejection fraction. Clin Hemorheol Microcirc. 2021;77(4):425\u201333. https:\/\/doi.org\/10.3233\/CH-201032.","journal-title":"Clin Hemorheol Microcirc"},{"issue":"19","key":"7830_CR37","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","volume":"54","author":"F Triposkiadis","year":"2009","unstructured":"Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure: physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54(19):1747\u201362. https:\/\/doi.org\/10.1016\/j.jacc.2009.05.015.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"7830_CR38","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3390\/ijms26031204","volume":"26","author":"ME Kim","year":"2025","unstructured":"Kim ME, Lee JS. Advances in the regulation of inflammatory mediators in nitric oxide synthase: implications for disease modulation and therapeutic approaches. Int J Mol Sci. 2025;26(3):1204. https:\/\/doi.org\/10.3390\/ijms26031204.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"7830_CR39","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1152\/physrev.00059.2021","volume":"103","author":"AF Russo","year":"2023","unstructured":"Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev. 2023;103(2):1565\u2013644. https:\/\/doi.org\/10.1152\/physrev.00059.2021.","journal-title":"Physiol Rev"},{"issue":"1","key":"7830_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1161\/CIRCRESAHA.115.302922","volume":"115","author":"K Sharma","year":"2014","unstructured":"Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res. 2014;115(1):79\u201396. https:\/\/doi.org\/10.1161\/CIRCRESAHA.115.302922.","journal-title":"Circ Res"},{"issue":"3","key":"7830_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1046\/j.1365-2125.1997.00545.x","volume":"43","author":"G McDowell","year":"1997","unstructured":"McDowell G, Coutie W, Shaw C, et al. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on Circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997;43(3):329\u201332. https:\/\/doi.org\/10.1046\/j.1365-2125.1997.00545.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"21","key":"7830_CR42","doi-asserted-by":"publisher","first-page":"e14269","DOI":"10.14814\/phy2.14269","volume":"7","author":"A Kumar","year":"2019","unstructured":"Kumar A, Supowit S, Potts JD, DiPette DJ. Alpha-calcitonin gene\u2010related peptide prevents pressure\u2010overload induced heart failure: role of apoptosis and oxidative stress. Physiol Rep. 2019;7(21):e14269. https:\/\/doi.org\/10.14814\/phy2.14269.","journal-title":"Physiol Rep"},{"key":"7830_CR43","doi-asserted-by":"publisher","first-page":"173205","DOI":"10.1016\/j.ejphar.2020.173205","volume":"881","author":"I Sohn","year":"2020","unstructured":"Sohn I, Sheykhzade M, Edvinsson L, Sams A. The effects of CGRP in vascular tissue\u2014classical vasodilation, shadowed effects and systemic dilemmas. Eur J Pharmacol. 2020;881:173205. https:\/\/doi.org\/10.1016\/j.ejphar.2020.173205.","journal-title":"Eur J Pharmacol"},{"key":"7830_CR44","doi-asserted-by":"publisher","first-page":"1204734","DOI":"10.3389\/fneur.2023.1204734","volume":"14","author":"MA Al-Karagholi","year":"2023","unstructured":"Al-Karagholi MA, Kalatharan V, Fagerberg PS, Amin FM. The vascular role of CGRP: a systematic review of human studies. Front Neurol. 2023;14:1204734. https:\/\/doi.org\/10.3389\/fneur.2023.1204734.","journal-title":"Front Neurol"},{"key":"7830_CR45","doi-asserted-by":"publisher","first-page":"826122","DOI":"10.3389\/fphys.2022.826122","volume":"13","author":"A Kumar","year":"2022","unstructured":"Kumar A, Williamson M, Hess A, et al. Alpha-calcitonin gene related peptide: new therapeutic strategies for the treatment and prevention of cardiovascular disease and migraine. Front Physiol. 2022;13:826122. https:\/\/doi.org\/10.3389\/fphys.2022.826122.","journal-title":"Front Physiol"},{"issue":"5","key":"7830_CR46","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1002\/ehf2.14916","volume":"11","author":"AH Behnoush","year":"2024","unstructured":"Behnoush AH, Khalaji A, Fazlollahpour-Naghibi A, et al. Circulating brain\u2010derived neurotrophic factor levels and heart failure: a systematic review and meta\u2010analysis. ESC Heart Fail. 2024;11(5):3253\u201363. https:\/\/doi.org\/10.1002\/ehf2.14916.","journal-title":"ESC Heart Fail"},{"issue":"6","key":"7830_CR47","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies\u2014successful translation from bench to clinic. Nat Rev Neurol. 2018;14(6):338\u201350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1.","journal-title":"Nat Rev Neurol"},{"key":"7830_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.peptides.2016.12.002","volume":"88","author":"JB Pawlak","year":"2017","unstructured":"Pawlak JB, Wetzel-Strong SE, Dunn MK, Caron KM. Cardiovascular effects of exogenous adrenomedullin and CGRP in ramp and calcrl deficient mice. Peptides. 2017;88:1\u20137. https:\/\/doi.org\/10.1016\/j.peptides.2016.12.002.","journal-title":"Peptides"},{"issue":"1","key":"7830_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12933-020-01029-0","volume":"19","author":"K Katsurada","year":"2020","unstructured":"Katsurada K, Nandi SS, Zheng H, et al. GLP-1 mediated diuresis and natriuresis are blunted in heart failure and restored by selective afferent renal denervation. Cardiovasc Diabetol. 2020;19(1):57. https:\/\/doi.org\/10.1186\/s12933-020-01029-0.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"7830_CR50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/13543784.2019.1551357","volume":"28","author":"J Tamargo","year":"2019","unstructured":"Tamargo J, Caballero R, Delpon E. New drugs in preclinical and early stage clinical development in the treatment of heart failure. Expert Opin Investig Drugs. 2019;28(1):51\u201371. https:\/\/doi.org\/10.1080\/13543784.2019.1551357.","journal-title":"Expert Opin Investig Drugs"},{"key":"7830_CR51","doi-asserted-by":"publisher","unstructured":"Clark-Price SC, Fischer JR. Physiology, pathophysiology, and anesthetic management of patients with renal disease. Vet Anesth Analg 2024 Jun 26:922\u201343. https:\/\/doi.org\/10.1002\/9781119830306.ch43","DOI":"10.1002\/9781119830306.ch43"},{"issue":"23","key":"7830_CR52","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.2174\/092986711796642562","volume":"18","author":"A Kaparianos","year":"2011","unstructured":"Kaparianos A, Argyropoulou E. Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. Curr Med Chem. 2011;18(23):3506\u201315. https:\/\/doi.org\/10.2174\/092986711796642562.","journal-title":"Curr Med Chem"},{"issue":"11","key":"7830_CR53","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1161\/CIRCRESAHA.114.302589","volume":"114","author":"VG Florea","year":"2014","unstructured":"Florea VG, Cohn JN. The autonomic nervous system and heart failure. Circ Res. 2014;114(11):1815\u201326. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.302589.","journal-title":"Circ Res"},{"issue":"1\u20133","key":"7830_CR54","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejphar.2004.02.010","volume":"488","author":"XP Qin","year":"2004","unstructured":"Qin XP, Ye F, Hu CP, et al. Effect of calcitonin gene-related peptide on angiotensin II-induced proliferation of rat vascular smooth muscle cells. Eur J Pharmacol. 2004;488(1\u20133):45\u20139. https:\/\/doi.org\/10.1016\/j.ejphar.2004.02.010.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"7830_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3892\/mmr.2020.11665","volume":"23","author":"WJ Ma","year":"2021","unstructured":"Ma WJ, Yin YC, Zhang BK, et al. Calcitonin gene-related peptide-mediated Pharmacological effects in cardiovascular and Gastrointestinal diseases. Mol Med Rep. 2021;23(1):27. https:\/\/doi.org\/10.3892\/mmr.2020.11665.","journal-title":"Mol Med Rep"},{"key":"7830_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5935\/abc.20160005","volume":"106","author":"PS Azevedo","year":"2015","unstructured":"Azevedo PS, Polegato BF, Minicucci MF, et al. Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and Pharmacologic treatment. Arq Bras Cardiol. 2015;106:62\u20139. https:\/\/doi.org\/10.5935\/abc.20160005.","journal-title":"Arq Bras Cardiol"},{"issue":"5","key":"7830_CR57","doi-asserted-by":"publisher","first-page":"165","DOI":"10.31083\/j.rcm2305165","volume":"23","author":"A Caturano","year":"2022","unstructured":"Caturano A, Vetrano E, Galiero R, et al. Cardiac hypertrophy: from pathophysiological mechanisms to heart failure development. Rev Cardiovasc Med. 2022;23(5):165. https:\/\/doi.org\/10.31083\/j.rcm2305165.","journal-title":"Rev Cardiovasc Med"},{"issue":"2","key":"7830_CR58","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1002\/j.2040-4603.2015.tb00624.x","volume":"5","author":"A Takawale","year":"2015","unstructured":"Takawale A, Sakamuri SS, Kassiri Z. Extracellular matrix communication and turnover in cardiac physiology and pathology. Compr Physiol. 2015;5(2):687\u2013719. https:\/\/doi.org\/10.1002\/j.2040-4603.2015.tb00624.x.","journal-title":"Compr Physiol"},{"key":"7830_CR59","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejphar.2018.10.023","volume":"843","author":"WQ Li","year":"2019","unstructured":"Li WQ, Tan SL, Li XH, et al. Calcitonin gene\u2013related peptide inhibits cardiac fibroblast senescence in cardiac fibrosis via upregulating Klotho expression. Eur J Pharmacol. 2019;843:96\u2013103. https:\/\/doi.org\/10.1016\/j.ejphar.2018.10.023.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"7830_CR60","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.bcp.2014.04.011","volume":"90","author":"FG Spinale","year":"2014","unstructured":"Spinale FG, Villarreal F. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014;90(1):7\u201315. https:\/\/doi.org\/10.1016\/j.bcp.2014.04.011.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"7830_CR61","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1007\/s12350-021-02678-8","volume":"29","author":"S Bentsen","year":"2022","unstructured":"Bentsen S, Sams A, Hasbak P, et al. Myocardial perfusion recovery induced by an \u03b1-calcitonin gene-related peptide analogue. J Nucl Cardiol. 2022;29(5):2090\u20139. https:\/\/doi.org\/10.1007\/s12350-021-02678-8.","journal-title":"J Nucl Cardiol"},{"issue":"1","key":"7830_CR62","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3892\/etm.2017.5423","volume":"15","author":"Y Yuan","year":"2018","unstructured":"Yuan Y, Yang S, Li C, et al. Effect of Recombinant adeno-associated virus expressing calcitonin gene-related peptide on a chick embryo umbilical artery vasospasm model. Exp Ther Med. 2018;15(1):145\u201351. https:\/\/doi.org\/10.3892\/etm.2017.5423.","journal-title":"Exp Ther Med"},{"issue":"4","key":"7830_CR63","doi-asserted-by":"publisher","first-page":"5168","DOI":"10.3892\/mmr.2018.8494","volume":"17","author":"Y Yang","year":"2018","unstructured":"Yang Y, Chen Q, Jia S, et al. Involvement of TRPV1 in the expression and release of calcitonin gene-related peptide induced by Rutaecarpine. Mol Med Rep. 2018;17(4):5168\u201374. https:\/\/doi.org\/10.3892\/mmr.2018.8494.","journal-title":"Mol Med Rep"},{"issue":"2","key":"7830_CR64","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1161\/01.HYP.37.2.728","volume":"37","author":"SC Supowit","year":"2001","unstructured":"Supowit SC, Zhao H, DiPette DJ. Nerve growth factor enhances calcitonin gene-related peptide expression in spontaneously hypertensive rats. Hypertension. 2001;37(2):728\u201332. https:\/\/doi.org\/10.1161\/01.HYP.37.2.728.","journal-title":"Hypertension"},{"issue":"3","key":"7830_CR65","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/WCO.0b013e32832b2427","volume":"22","author":"A Recober","year":"2009","unstructured":"Recober A, Russo AF. Calcitonin gene-related peptide: an update on the biology. Curr Opin Neurol. 2009;22(3):241\u20136. https:\/\/doi.org\/10.1097\/WCO.0b013e32832b2427.","journal-title":"Curr Opin Neurol"},{"issue":"7","key":"7830_CR66","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1007\/s00415-020-09707-5","volume":"268","author":"X Zhao","year":"2021","unstructured":"Zhao X, Xu X, Li Q. Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis. J Neurol. 2021;268(7):2364\u201376. https:\/\/doi.org\/10.1007\/s00415-020-09707-5.","journal-title":"J Neurol"},{"issue":"7","key":"7830_CR67","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"M Ashina","year":"2022","unstructured":"Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21(7):597\u2013607. https:\/\/doi.org\/10.1016\/S1474-4422(22)00185-5.","journal-title":"Lancet Neurol"},{"issue":"8","key":"7830_CR68","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/0002-9149(91)90531-O","volume":"67","author":"YC Shekhar","year":"1991","unstructured":"Shekhar YC, Anand IS, Sarma R, et al. Effects of prolonged infusion of human alpha calcitonin gene-related peptide on hemodynamics, renal blood flow and hormone levels in congestive heart failure. Am J Cardiol. 1991;67(8):732\u20136. https:\/\/doi.org\/10.1016\/0002-9149(91)90531-O.","journal-title":"Am J Cardiol"},{"issue":"1","key":"7830_CR69","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.xphs.2021.06.034","volume":"111","author":"K Srinivasan","year":"2022","unstructured":"Srinivasan K, Kozminski K, Zhang Y, et al. Pharmacological, pharmacokinetic, pharmacodynamic and physicochemical characterization of FE 205030: a potent, fast acting, injectable CGRP receptor antagonist for the treatment of acute episodic migraine. J Pharm Sci. 2022;111(1):247\u201361. https:\/\/doi.org\/10.1016\/j.xphs.2021.06.034.","journal-title":"J Pharm Sci"},{"issue":"1","key":"7830_CR70","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/cne.10565","volume":"458","author":"W Ma","year":"2003","unstructured":"Ma W, Chabot JG, Powell KJ, Jhamandas K, Dickerson IM, Quirion R. Localization and modulation of calcitonin gene-related peptide-receptor component protein-immunoreactive cells in the rat central and peripheral nervous systems. J Comp Neurol. 2003;458(1):38\u201352. https:\/\/doi.org\/10.1002\/cne.10565.","journal-title":"J Comp Neurol"},{"issue":"4","key":"7830_CR71","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1097\/HJH.0000000000002125","volume":"48","author":"D Bell","year":"1996","unstructured":"Bell D, McDermott BJ. Calcitonin gene-related peptide in the cardiovascular system: characterization of receptor populations and their (patho)physiological significance. Pharmacol Rev. 1996;48(4):253\u201388. https:\/\/doi.org\/10.1097\/HJH.0000000000002125.","journal-title":"Pharmacol Rev"},{"issue":"6","key":"7830_CR72","doi-asserted-by":"publisher","first-page":"H2115","DOI":"10.1152\/ajpheart.00198.2010","volume":"299","author":"SC Supowit","year":"2010","unstructured":"Supowit SC, Zhao H, Hallman DM, DiPette DJ. Alpha-calcitonin gene-related peptide is a survival factor that protects cardiomyocytes from hypoxia-induced apoptosis. Am J Physiol Heart Circ Physiol. 2010;299(6):H2115\u201322. https:\/\/doi.org\/10.1152\/ajpheart.00198.2010.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"6","key":"7830_CR73","doi-asserted-by":"publisher","first-page":"H830","DOI":"10.1152\/ajpheart.00826.2012","volume":"304","author":"SC Supowit","year":"2013","unstructured":"Supowit SC, Zhao H, Hallman DM, DiPette DJ. Role of alpha-calcitonin gene-related peptide in the Attenuation of cardiac hypertrophy through Inhibition of oxidative stress. Am J Physiol Heart Circ Physiol. 2013;304(6):H830\u201340. https:\/\/doi.org\/10.1152\/ajpheart.00826.2012.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"7830_CR74","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41440-020-0388-0","volume":"43","author":"T Koyama","year":"2020","unstructured":"Koyama T, Kikuya M, Utsugi MT, et al. Role of calcitonin gene-related peptide in the cardiovascular system\u2014special focus on vascular and myocardial effects. Hypertens Res. 2020;43(4):265\u201375. https:\/\/doi.org\/10.1038\/s41440-020-0388-0.","journal-title":"Hypertens Res"},{"issue":"3","key":"7830_CR75","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1161\/CIRCRESAHA.109.202879","volume":"106","author":"KY Chan","year":"2010","unstructured":"Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of calcitonin gene-related peptide receptor and receptor activity\u2013modifying protein 1 expression in human coronary arteries. Circ Res. 2010;106(3):403\u201311. https:\/\/doi.org\/10.1161\/CIRCRESAHA.109.202879.","journal-title":"Circ Res"},{"issue":"2","key":"7830_CR76","doi-asserted-by":"publisher","first-page":"H672","DOI":"10.1152\/ajpheart.00739.2004","volume":"288","author":"SC Supowit","year":"2005","unstructured":"Supowit SC, Potts JD, Zhao H, et al. Calcitonin gene-related peptide protects against pressure overload-induced heart failure. Am J Physiol Heart Circ Physiol. 2005;288(2):H672\u20138. https:\/\/doi.org\/10.1152\/ajpheart.00739.2004.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"7830_CR77","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/head.12113","volume":"3","author":"T Schlereth","year":"2013","unstructured":"Schlereth T, Birklein F. The role of calcitonin gene-related peptide in inflammation, pain and migraine. Headache Currents. 2013;3(1):26\u201331. https:\/\/doi.org\/10.1111\/head.12113.","journal-title":"Headache Currents"},{"issue":"4","key":"7830_CR78","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/sj.bjp.0704756","volume":"136","author":"KE Wiley","year":"2002","unstructured":"Wiley KE, Davenport AP. Physiological antagonism between calcitonin gene-related peptide and endothelin-1 in human conductance and resistance arteries. Br J Pharmacol. 2002;136(4):623\u201332. https:\/\/doi.org\/10.1038\/sj.bjp.0704756.","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"7830_CR79","doi-asserted-by":"publisher","first-page":"S193","DOI":"10.1038\/sj.bjp.0706458","volume":"147","author":"S Moncada","year":"2006","unstructured":"Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol. 2006;147(Suppl 1):S193\u2013201. https:\/\/doi.org\/10.1038\/sj.bjp.0706458.","journal-title":"Br J Pharmacol"},{"key":"7830_CR80","doi-asserted-by":"publisher","first-page":"826122","DOI":"10.3389\/fphys.2022.826122","volume":"13","author":"H Zhao","year":"2022","unstructured":"Zhao H, DiPette DJ, Supowit SC. The protective role of alpha-calcitonin gene-related peptide in the cardiovascular system. Front Physiol. 2022;13:826122. https:\/\/doi.org\/10.3389\/fphys.2022.826122.","journal-title":"Front Physiol"},{"issue":"6","key":"7830_CR81","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1161\/HYPERTENSIONAHA.108.113225","volume":"51","author":"A Zeller","year":"2008","unstructured":"Zeller A, Wenzl MV, Mayer S, et al. Calcitonin gene-related peptide deficiency in mice increases susceptibility to pressure overload-induced heart failure. Hypertension. 2008;51(6):1695\u2013701. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.108.113225.","journal-title":"Hypertension"},{"issue":"7","key":"7830_CR82","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/ejhf.665","volume":"18","author":"F Triposkiadis","year":"2016","unstructured":"Triposkiadis F, Giamouzis G, Parissis J, et al. Reframing the association and significance of comorbidities in heart failure. Eur J Heart Fail. 2016;18(7):744\u201358. https:\/\/doi.org\/10.1002\/ejhf.665.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"7830_CR83","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/heart.87.1.5","volume":"87","author":"JG Lainchbury","year":"2002","unstructured":"Lainchbury JG, Richards AM. Epidemiology and natural history of heart failure. Heart. 2002;87(1):5\u20138. https:\/\/doi.org\/10.1136\/heart.87.1.5.","journal-title":"Heart"},{"issue":"7","key":"7830_CR84","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","volume":"31","author":"G Mancia","year":"2013","unstructured":"Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens. 2013;31(7):1281\u2013357. https:\/\/doi.org\/10.1097\/01.hjh.0000431740.32696.cc.","journal-title":"J Hypertens"},{"issue":"27","key":"7830_CR85","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37(27):2129\u2013200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128.","journal-title":"Eur Heart J"},{"issue":"17","key":"7830_CR86","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","volume":"79","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American college of Cardiology\/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79(17):e263\u2013421. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.012.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"7830_CR87","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cardfail.2021.01.022","volume":"27","author":"B Bozkurt","year":"2021","unstructured":"Bozkurt B, Coats AJ, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the ESC, Japanese heart failure society and writing committee of the universal definition of heart failure. J Card Fail. 2021;27(4):387\u2013413. https:\/\/doi.org\/10.1016\/j.cardfail.2021.01.022.","journal-title":"J Card Fail"},{"issue":"36","key":"7830_CR88","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"5","key":"7830_CR89","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1212\/WNL.0000000000008743","volume":"94","author":"D Kudrow","year":"2020","unstructured":"Kudrow D, Pascual J, Winner PK, et al. Vascular safety of erenumab for migraine prevention. Neurology. 2020;94(5):e497\u2013510. . https:\/\/doi.org\/10.1212\/WNL.0000000000008743","journal-title":"Neurology"},{"key":"7830_CR90","doi-asserted-by":"publisher","first-page":"101","DOI":"10.23937\/2378-3001\/1410101","volume":"7","author":"K Boldig","year":"2020","unstructured":"Boldig K, Butala N. Migraines and CGRP monoclonal antibodies: a review of cardiovascular side effects and safety profile. Int J Neurol Neurother. 2020;7:101. https:\/\/doi.org\/10.23937\/2378-3001\/1410101.","journal-title":"Int J Neurol Neurother"},{"key":"7830_CR91","doi-asserted-by":"publisher","unstructured":"Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50(25):2357\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2007.09.021.","DOI":"10.1016\/j.jacc.2007.09.021"},{"issue":"10","key":"7830_CR92","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1001\/jama.288.10.1252","volume":"288","author":"RS Vasan","year":"2002","unstructured":"Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. JAMA. 2002;288(10):1252\u20139. https:\/\/doi.org\/10.1001\/jama.288.10.1252.","journal-title":"JAMA"},{"issue":"9970","key":"7830_CR93","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/S0140-6736(14)61889-4","volume":"385","author":"E Braunwald","year":"2015","unstructured":"Braunwald E. The war against heart failure: the lancet lecture. Lancet. 2015;385(9970):812\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(14)61889-4.","journal-title":"Lancet"},{"issue":"10","key":"7830_CR94","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.ejheart.2008.08.005","volume":"10","author":"K Dickstein","year":"2008","unstructured":"Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur J Heart Fail. 2008;10(10):933\u201389. https:\/\/doi.org\/10.1016\/j.ejheart.2008.08.005.","journal-title":"Eur J Heart Fail"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-025-07830-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-025-07830-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T09:07:59Z","timestamp":1784624879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-025-07830-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,17]]},"references-count":94,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7830"],"URL":"https:\/\/doi.org\/10.1007\/s10557-025-07830-x","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,17]]},"assertion":[{"value":"12 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}